ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Shidlovski / shutterstock.com

Studies Suggest Similar Risks for Biologics vs. Conventional Therapies for Rheumatoid Arthritis

Bryn Nelson, PhD  |  May 15, 2020

Two new studies delving into the relative safety of biologic drugs prescribed for rheumatoid arthritis (RA) have concluded that real-world applications of abatacept and tumor necrosis factor inhibitors (TNFi’s) are comparable to more conventional therapies in their associated risk of serious infections. Triple Therapy One study, in Arthritis Care & Research, found the risk of…

Filed under:ConditionsDrug UpdatesResearch RheumRheumatoid Arthritis Tagged with:abatacepttriple therapytumor necrosis factor inhibitor (TNFi)

The Potential for Telemedicine to Supplement In-Person Care

Elizabeth Park, MD  |  May 15, 2020

Even before I started my rheuma­tology fellowship, I knew it would be a demanding career, diagnosing complex diseases with only a few management options in seriously ill patients. What I didn’t appreciate as much before is how badly we are needed across the country. According to the 2018 outcomes report from the National Resident Matching…

Filed under:Practice SupportTechnology Tagged with:Fellows-in-Trainingtelemedicinetelerheumatology

The COVID-19 Global Rheumatology Alliance: Its Genesis, Development & Goals

Philip C. Robinson, MBChB, PhD, FRACP  |  May 8, 2020

Editor’s note: We are sad to announce that we have learned of the passing of Dr. Philip C. Robinson. We will share more as it becomes available, but in the meantime, we wanted to repost this article he wrote for The Rheumatologist early in the pandemic. Dr. Robinson also took the photo of the full-arc rainbow  below.

Filed under:Practice SupportQuality Assurance/Improvement Tagged with:COVID-19COVID-19 Global Rheumatology Alliance

Adapting Care for Pediatric Patients & Parents During the Pandemic: Q&A with Sangeeta Sule, MD, PhD

Susan Bernstein  |  May 1, 2020

Social distancing and telemedicine are creating unique challenges for pediatric rheumatologists to care for their patients—many of whom are 5 years old or younger. Sangeeta Sule, MD, PhD, discusses how her clinic is adapting…

Filed under:Conditions

The author in her home office.

On Pandemics & Uncertainty: One Rheumatologist’s Story

Belinda Birnbaum, MD  |  April 24, 2020

As the mystery solvers, we are supposed to be comfortable with the unknown, but how does that translate when COVID-19 hits home? A rheumatologist contracts COVID-19.

Filed under:ConditionsOpinionSpeak Out Rheum Tagged with:BirnbaumCOVID-19

The Latest Advances in Sjögren’s, Scleroderma, RA, Gout & More

Jason Liebowitz, MD, FACR  |  April 15, 2020

ATLANTA—At the ACR/ARP 2019 Annual Meeting, several widely renowned experts across an array of specialty subjects provided a comprehensive and compelling review of advances in the understanding, diagnosis and treatment of a number of rheumatologic conditions. Sjögren’s Syndrome Frederick Vivino, MD, FACR, chief of rheumatology at Penn Presbyterian Medical Center and professor of clinical medicine…

Filed under:Clinical Criteria/GuidelinesConditionsGout and Crystalline ArthritisGuidanceMeeting ReportsOther Rheumatic ConditionsRheumatoid ArthritisSystemic Sclerosis Tagged with:2019 ACR/ARP Annual Meetingmacrophage activation syndrome

Experts Offer Tips for Saving Time on Electronic Medical Records

Thomas R. Collins  |  April 15, 2020

ATLANTA—“Bane of our existence” and “pajama time”—the dreaded time spent at night catching up on documentation—are a couple of phrases associated with the electronic medical record (EMR). To try to ease the frustration and limit the amount of time physicians have to spend using the systems, two experts reviewed tools and tricks for Epic and…

Filed under:EMRsMeeting ReportsTechnology Tagged with:2019 ACR/ARP Annual Meeting

Not All Rheumatoid Factor-Positive Tests Mean RA

Francis Essien, DO, & Matthew B. Carroll, MD, FACP, FACR  |  April 15, 2020

Angioimmunoblastic T cell lymphoma (AITL) is an aggressive, peripheral T cell, non-Hodgkin’s lymphoma with an incidence of 0.05 cases per 100,000 person-years in the U.S., and it typically manifests in adults older than 60 years.1,2 AITL was previously known as angio­immunoblastic lymphadenopathy with dysproteinemia, immunoblastic lympha­denopathy or lymphogranulomatosis X, due to the hypothesis that the…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Cancercase reportRheumatoid Factor

2 Patients on Different DMARDs Experience Different COVID-19 Disease Courses

Luis A. Marcos, MD, MPH, Saika Sharmeen, DO, Jaime Gonzalez, MD, Qingping Yao, MD, PhD, Bettina Fries, MD, & Jack Fuhrer, MD  |  April 13, 2020

In March 2020, an elderly married couple living on Long Island, N.Y., presented to our emergency department with symptoms suspicious for COVID-19 infection. The wife, a-76-year-old woman, presented with complaints of subjective fevers, minimal dry cough and headaches of one-week duration. She denied having any chills, rhinorrhea, diarrhea, abdominal pain or shortness of breath. Two…

Filed under:Conditions Tagged with:COVID-19

No Evidence to Support Biologic Switching Guidelines for JIA

Marilynn Larkin  |  April 1, 2020

NEW YORK (Reuters Health)—For young people with juvenile idiopathic arthritis (JIA) who don’t achieve disease control, switching to a different class of biologic is unlikely to be beneficial, researchers say. The observational study yielded no evidence to support or refute the 2015 National Health Service England guidelines, which recommend switching most patients to a second…

Filed under:ConditionsOther Rheumatic ConditionsPediatric Conditions Tagged with:BiologicsJIAjuvenile idiopathic arthritis (JIA)Pediatric

  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 107
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences